Odonate Therapeutics (ODT) PT Lowered to $4 at Goldman Sachs, Following Important Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ODT Hot Sheet
Price: $1.12 --0%
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on Odonate Therapeutics (NASDAQ: ODT) to $4.00 (from $11.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Deckers Outdoor (DECK) PT Lowered to $100 at Williams Trading
- CoreWeave (CRWV) PT Lowered to $105 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
